Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma

NCT05154994 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Infiltrating Urothelial Carcinoma, Sarcomatoid Variant
Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Unresectable Urothelial Carcinoma

Interventions

DRUG: Belinostat
BIOLOGICAL: Durvalumab

Sponsor

University of Utah

Collaborators

[object Object]